Display options
Cite
Tariq T, Dawdy J, Goyal S, et al. Hepatic Sinusoidal Obstruction Syndrome in a Patient With Multiple Myeloma Treated With CyBorD. ACG Case Rep J. 2019;6(7):e00103doi: 10.14309/crj.0000000000000103.
Tariq, T., Dawdy, J., Goyal, S., Mohamad, B., Singh, M., Mutchnick, M., & Ehrinpreis, M. (2019). Hepatic Sinusoidal Obstruction Syndrome in a Patient With Multiple Myeloma Treated With CyBorD. ACG case reports journal, 6(7), e00103. https://doi.org/10.14309/crj.0000000000000103
Tariq, Tooba, et al. "Hepatic Sinusoidal Obstruction Syndrome in a Patient With Multiple Myeloma Treated With CyBorD." ACG case reports journal vol. 6,7 (2019): e00103. doi: https://doi.org/10.14309/crj.0000000000000103
Tariq T, Dawdy J, Goyal S, Mohamad B, Singh M, Mutchnick M, Ehrinpreis M. Hepatic Sinusoidal Obstruction Syndrome in a Patient With Multiple Myeloma Treated With CyBorD. ACG Case Rep J. 2019 Jul 25;6(7):e00103. doi: 10.14309/crj.0000000000000103. eCollection 2019 Jul. PMID: 31620512; PMCID: PMC6722380.
Copy Download .nbib Format: NLM
Share it on

ACG Case Rep J. 2019 Jul 25;6(7):e00103. doi: 10.14309/crj.0000000000000103. eCollection 2019 Jul.

Hepatic Sinusoidal Obstruction Syndrome in a Patient With Multiple Myeloma Treated With CyBorD.

ACG case reports journal

Tooba Tariq, John Dawdy, Sachin Goyal, Bashar Mohamad, Manmeet Singh, Milton Mutchnick, Murray Ehrinpreis

Affiliations

  1. Department of Internal Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI.
  2. Department of Internal Medicine, Detroit Medical Center/Wayne State University, Detroit, MI.
  3. Department of Gastroenterology, Detroit Medical Center/Wayne State University, Detroit, MI.

PMID: 31620512 PMCID: PMC6722380 DOI: 10.14309/crj.0000000000000103

Abstract

Hepatic sinusoidal obstruction syndrome (SOS) is a life-threatening state generally occurring as a complication of conditioning regimens used for hematopoietic stem cell transplant. Hepatic SOS after a standard dose of chemotherapy in malignancies is rare, and there are only a few cases in pediatric literature. We report a 56-year-old man with multiple myeloma who experienced SOS after being initiated on chemotherapy including cyclophosphamide, dexamethasone, and bortezomib and who experienced a delay in treatment with defibrotide, because it is currently approved by the Food and Drug Administration for only patients who develop SOS after hematopoietic stem cell transplant.

© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.

References

  1. Br J Haematol. 2018 Jun;181(6):816-827 - PubMed
  2. Pediatr Blood Cancer. 2006 Apr;46(4):521-3 - PubMed
  3. Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):539-541 - PubMed
  4. Br J Cancer. 2006 May 8;94(9):1226-30 - PubMed
  5. Pediatr Blood Cancer. 2018 Oct;65(10):e27269 - PubMed
  6. Transplantation. 1987 Dec;44(6):778-83 - PubMed
  7. Br J Haematol. 2017 Jul;178(1):112-118 - PubMed
  8. Biol Blood Marrow Transplant. 2016 Oct;22(10):1874-1882 - PubMed
  9. Intern Med. 2017;56(4):395-400 - PubMed
  10. Ann Pharmacother. 2006 Apr;40(4):767-70 - PubMed
  11. Blood. 2016 Mar 31;127(13):1656-65 - PubMed
  12. Blood. 2003 Sep 1;102(5):1578-82 - PubMed
  13. Bone Marrow Transplant. 2016 Mar;51(3):403-9 - PubMed
  14. Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004 - PubMed
  15. Am J Pathol. 1987 Jun;127(3):549-58 - PubMed

Publication Types